Biotech is repositioning itself!
Investors are now asking more questions about the short, near and long term viability of healthcare stocks. In a slowly rebounding market, despite today’s volatility; there is a silver lining; smaller, leaner healthcare companies are emerging stronger from the past crisis.
There is no quick fix …
- The market’s slow rebound is also an opportunity for investors,
- Share purchase must be focused on the questions related to clinical and regulatory viability as the market is currently dominated by behavioral forces and non-believing investors.
According to Healthcare Sector- Global Market -US INDEX (Business Week)
| Performance | |||
| Industry | 1 Month | 3 Month | YTD |
| Health Care 382 Companies |
+8.67% | +10.79% | +6.59% |
| Pharmaceuticals, Biotechnology & Life Sciences 181 Companies |
+8.03% | +11.35% | +2.70% |
| Health Care Equipment & Services 201 Companies |
+9.91% | +9.82% | +14.53% |
August started out well … so we should see further appreciation as key decisions are due from FDA in the next month. The best advice is to monitor those healthcare companies whose institutional investors have recently added and stayed in an investment while manyothers have left.
Categories: Healthcare, Independent Equity Research
